Cantor Fitzgerald Predicts Septerna FY2024 Earnings

Septerna, Inc. (NASDAQ:SEPN) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Septerna in a research report issued on Tuesday, November 19th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($5.19) for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. TD Cowen initiated coverage on shares of Septerna in a research report on Tuesday. They set a “buy” rating on the stock. Wells Fargo & Company initiated coverage on Septerna in a research report on Tuesday. They set an “overweight” rating and a $43.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday. They set an “overweight” rating and a $38.00 price target on the stock.

Septerna Stock Down 3.2 %

SEPN stock opened at $21.79 on Friday. Septerna has a 12 month low of $18.62 and a 12 month high of $26.34.

Insider Buying and Selling

In related news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the business’s stock in a transaction on Monday, October 28th. The shares were bought at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the acquisition, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.